371P Palbociclib plus endocrine therapy in clinically relevant HR+/HER2- mBC subgroups: A real-world multicenter studyR. Buonaiuto, C. De Angelis, R. Esposito et al.|ESMO Open|2025Cited by 0
209P Comparative analysis of clinician and AI decision-making in HR+/HER2- early breast cancer within routine clinical practice and clinical trialR. Buonaiuto, Mario Giuliano, F.P. Mangiacotti et al.|ESMO Open|2025Cited by 0